Kodiak Sciences Reports $65.6 Million Net Loss in Q2 2026, Increased R&D Expenses

Kodiak Sciences Inc. reported a net loss of $65.6 million for the second quarter of 2026, compared to a loss of $54.3 million in the same period of 2025. For the first half of 2026, the company’s net loss totaled $123.8 million, up from $111.8 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $56.1 million in the second quarter, a 29% increase from $42.8 million in the same quarter of 2025. The total operating expenses for the first half of 2026 were $126.6 million, compared to $114.6 million in the same period last year.

In terms of financial position, Kodiak's cash and cash equivalents decreased to $125.9 million as of June 30, 2026, down from $209.9 million at the end of 2025. The company’s total assets also fell to $256.8 million from $351.5 million over the same period. The accumulated deficit increased to $1.7 billion, reflecting the ongoing investment in research and development without any product revenue generated to date. The company continues to rely on equity financing and the sale of future royalties to fund its operations.

Strategically, Kodiak is advancing its clinical pipeline, focusing on three late-stage product candidates: Zenkuda (tarcocimab), KSI-501, and KSI-101. Zenkuda has completed four Phase 3 studies and is currently in the DAYBREAK trial for wet AMD, with topline data expected in September 2026. KSI-501 is also in the DAYBREAK study, while KSI-101 is undergoing pivotal studies PEAK and PINNACLE, with results anticipated in late 2026 and early 2027. The company has made significant progress in its manufacturing capabilities, which it believes will support potential market share capture if its products receive regulatory approval.

Operationally, Kodiak's research and development expenses reflect increased activity in its clinical trials, particularly for KSI-501 and KSI-101, which saw substantial cost increases due to ramped-up production and trial activities. The company has also reduced general and administrative expenses, which fell to $10.8 million in the second quarter from $12.8 million a year earlier, primarily due to lower stock compensation expenses and reduced facility costs following a sublease agreement. As of June 30, 2026, Kodiak had 62.8 million shares outstanding, reflecting ongoing stock option exercises and vesting of restricted stock units.

Looking ahead, Kodiak Sciences acknowledges substantial doubt regarding its ability to continue as a going concern without additional capital. The company plans to raise further funds to support its operations and development activities, emphasizing the need for successful clinical outcomes and regulatory approvals to generate revenue. The ongoing macroeconomic uncertainties and potential disruptions could impact its financial condition and operational plans, necessitating careful monitoring of its liquidity and capital resources.